首页> 外文期刊>Chemotherapy Research and Practice >Neoadjuvant Treatment in Rectal Cancer: Actual Status
【24h】

Neoadjuvant Treatment in Rectal Cancer: Actual Status

机译:直肠癌的新辅助治疗:实际情况

获取原文
       

摘要

Neoadjuvant (preoperative) concomitant chemoradiotherapy (CRT) has become a standard treatment of locally advanced rectal adenocarcinomas. The clinical stages II (cT3-4, N0, M0) and III (cT1-4, N+, M0) according to International Union Against Cancer (IUCC) are concerned. It can reduce tumor volume and subsequently lead to an increase in complete resections (R0 resections), shows less toxicity, and improves local control rate. The aim of this review is to summarize actual approaches, main problems, and discrepancies in the treatment of locally advanced rectal adenocarcinomas.
机译:新辅助(术前)伴随放化疗已成为局部晚期直肠腺癌的标准治疗方法。根据国际抗癌联盟(IUCC),涉及临床分期II(cT3-4,N0,M0)和III分期(cT1-4,N +,M0)。它可以减少肿瘤体积,并随后导致完整切除(R0切除)的增加,毒性降低并提高局部控制率。这篇综述的目的是总结治疗局部晚期直肠腺癌的实际方法,主要问题和差异。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号